![]() |
市场调查报告书
商品编码
1764892
2031年亚太地区青光眼治疗市场预测 - 区域分析 - 按药物类别、适应症和配销通路Asia Pacific Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class, Indication, and Distribution Channel |
2023 年亚太青光眼治疗市场价值为 12.118 亿美元,预计到 2031 年将达到 15.9841 亿美元;预计 2023 年至 2031 年的复合年增长率为 3.5%。
穿戴式科技的发展推动亚太青光眼治疗市场
技术创新一直是任何生命科学学科(包括眼科学)的基础,因为现代设备是准确诊断和改进治疗的关键。治疗方法的进步使得青光眼的治疗得到改善。穿戴式青光眼诊断和治疗产品已成为潜在的解决方案。传统诊断技术提供可靠的眼压资料,而 Sensimed Triggerfish 等创新隐形眼镜则提供持续的眼压追踪。先进的药物洗脱隐形眼镜也正在成为青光眼治疗的潜在解决方案。 2023 年 3 月,SpyGlass Pharma 发布了其首次人体青光眼治疗试验的 6 个月资料。资料显示,其新的药物输送平台(一种带有药物洗脱垫的一体式疏水性丙烯酸人工水晶体)继续显着降低患有青光眼或眼高压患者的眼压。因此,此类现代穿戴式产品的开发可能会在未来几年推动对青光眼治疗的需求。
亚太青光眼治疗市场概况
亚太地区的青光眼治疗市场细分为中国、日本、印度、澳洲、韩国和亚太其他地区。该地区市场的成长归因于青光眼发病率的上升、老年人口的增加以及促进研究活动的投资激增。主要市场参与者正在采取合併、收购、产品发布和融资等策略来扩大其市场份额。 2023 年 2 月,兆科眼科的比马前列素噻吗洛尔滴眼液获得国家药品监督管理局 (NMPA) 的上市许可,用于治疗青光眼。 2023 年 2 月,参天製药股份有限公司的 STN1011101 滴眼液申请获得了 NMPA 的上市许可。这款不含防腐剂的配方含有 0.0015% 的他氟前列素和 0.5% 的噻吗洛尔,由参天製药和 AGC Inc. 共同开发。该药物旨在满足中国青光眼治疗中尚未满足的需求。
2022年2月发表在《BMC眼科期刊》的研究报告显示,中国是全球青光眼发生率最高的国家。此外,2020年,中国各类青光眼患者人数达1,558万人,预计2050年将激增至2,516万人。青光眼的高发生率预计将在未来推动该疾病治疗药物的成长。中国青光眼治疗市场的成长主要归功于市场参与者采取的各种成长策略以及人口老化的加剧。
亚太青光眼治疗市场收入及预测(2031年)(百万美元)
亚太青光眼治疗市场区隔
亚太青光眼治疗市场按药物类别、适应症、配销通路和国家分类。
依药物类别,亚太地区青光眼治疗市场细分为β受体阻断剂、α肾上腺素激动剂、前列腺素类似物、碳酸酐酶抑制剂、复方药物及其他。前列腺素类似物在2023年占据了最大的市场。
依适应症划分,亚太地区青光眼治疗市场分为开角型青光眼、闭角型青光眼及其他类型。 2023年,开角型青光眼占了最大的市场。
按配销通路划分,亚太地区青光眼治疗市场分为医院药房、零售药房和线上药房。 2023年,医院药局占了最大的市场份额。
按国家/地区划分,亚太地区青光眼治疗市场分为中国、日本、印度、澳洲、韩国和亚太其他地区。 2023年,中国占据亚太地区青光眼治疗市场的主导地位。
Alcon AG、AbbVie Inc、Bausch & Lomb Inc, LLC、Viatris Inc、Novartis AG、Sun Pharmaceutical Industries Ltd、Teva Pharmaceuticals Industries Ltd、Thea Pharma Inc 和 Santen Pharmaceutical Co., Ltd. 是亚太地区青光眼治疗市场领先的公司。
The Asia Pacific glaucoma therapeutics market was valued at US$ 1,211.80 million in 2023 and is expected to reach US$ 1,598.41 million by 2031; it is estimated to register a CAGR of 3.5% from 2023 to 2031.
Development of Wearable Technologies Fuels Asia Pacific Glaucoma Therapeutics Market
Technological innovation has always been fundamental to any discipline of life sciences, including ophthalmology, as modern devices are key to accurate diagnosis and improved treatments. Advancements in treatments have enabled the improved treatment of glaucoma. Wearable glaucoma diagnostics and therapeutics products have emerged as potential solutions. Conventional diagnostic techniques provide reliable intraocular pressure data, while innovative contact lenses such as Sensimed Triggerfish offer continuous IOP tracking. Advanced drug-eluting contact lenses are also emerging as a potential solution for glaucoma therapy. In March 2023, SpyGlass Pharma released 6-month data from its first-in-human glaucoma treatment trial. The data shows that its new drug delivery platform, which is a single-piece, hydrophobic acrylic intraocular lens with drug-eluting pads, continues to significantly lower IOP in patients suffering from glaucoma or ocular hypertension. Thus, the development of such modern wearable products is likely to propel the demand for glaucoma therapeutics in the coming years.
Asia Pacific Glaucoma Therapeutics Market Overview
The glaucoma therapeutics market in Asia Pacific is subsegmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Market growth in this region is ascribed to the rising incidence of glaucoma, the growing geriatric population, and surging investments to boost research activities. Key market players are adopting strategies such as mergers, acquisitions, product launches, and fundraising to expand their market presence. In February 2023, Zhaoke Ophthalmology's Bimatoprost Timolol eye drops received marketing authorization from the National Medical Products Administration (NMPA) for their use in glaucoma treatment. In February 2023, Santen Pharmaceutical Co., Ltd. received the marketing authorization from the NMPA for its application for STN1011101 eye drops. This preservative-free formulation containing tafluprost 0.0015% and timolol 0.5% was codeveloped by Santen and AGC Inc. The drug aims to address the unmet needs for glaucoma treatment in China.
A study published in the BMC Ophthalmology Journal in February 2022 reported that China has the highest rate of glaucoma in the world. Moreover, the country had 15.58 million people with all types of glaucoma in 2020, and the number is projected to spike up to 25.16 million by 2050. The high prevalence of glaucoma is expected to drive the growth of therapeutics to manage the disease in the future. The glaucoma therapeutics market growth in China is primarily attributed to various growth strategies adopted by market players and the increasing aging population.
Asia Pacific Glaucoma Therapeutics Market Revenue and Forecast to 2031 (US$ Million)
Asia Pacific Glaucoma Therapeutics Market Segmentation
The Asia Pacific glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.
Based on drug class, the Asia Pacific glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.
In terms of indication, the Asia Pacific glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.
By distribution channel, the Asia Pacific glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.
By country, the Asia Pacific glaucoma therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific glaucoma therapeutics market share in 2023.
Alcon AG, AbbVie Inc, Bausch & Lomb Inc, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the Asia Pacific glaucoma therapeutics market.